Jefferies analyst Andrew Tsai last night initiated coverage of Definium Therapeutics (DFTX) with a Buy rating and $30 price target The firm says a single dose of the company’s DT120 has produced a “strong” 48% remission rate in a Phase IIb trial for generalized anxiety disorder. Jefferies is 65%-75% confident that DT120 will generate “best-in-class” efficacy again in two Phase IIIs starting in Q2.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DFTX:
- Psychedelic: Analyst raises Compass, Definium, GH Research price targets
- Definium Therapeutics appoints Roger Adsett to board of directors
- Definium Therapeutics Expands Board, Appoints New Director
- Definium Therapeutics price target raised to $37 from $16 at Baird
- Definium Therapeutics price target raised to $36 from $20 at RBC Capital